Skip to main content

Table 3 Threshold effect analysis of eGFR on uric acid levels using piece-wise linear regression

From: Efficacy of different urinary uric acid indicators in patients with chronic kidney disease

Model Model I Model II
Various Male   Female   Total   Male   Female   Total
  Crude β/OR (95%CI) p value   Crude β/OR (95%CI) p value   Crude β/OR (95%CI) p value   Crude β/OR (95%CI) p value   Crude β/OR (95%CI) p value   Crude β/OR (95%CI) p value
FEur (%)          FEur (%)         
eGFR< 28.9 − 0.7 (− 0.8, − 0.6) < 0.001 eGFR< 8 −4.5 (−5.6, −3.4) < 0.001 eGFR< 15.9 − 1.4 (− 1.6, − 1.2) < 0.001 eGFR< 28.9 − 0.7 (− 0.8, − 0.6) < 0.001 eGFR< 8 − 4.5 (− 5.6, − 3.4) < 0.001 eGFR< 15.9 − 1.4 (− 1.6, − 1.2) < 0.001
eGFR≥28.9 −0.0 (− 0.1, − 0.0) 0.002 eGFR≥8 −0.1 (− 0.1, − 0.1) < 0.001 eGFR≥15.9 −0.1 (− 0.1, − 0.0) < 0.001 eGFR≥28.9 −0.0 (− 0.1, − 0.0) 0.002 eGFR≥8 −0.1 (− 0.1, − 0.1) < 0.001 eGFR≥15.9 −0.1 (− 0.1, − 0.0) < 0.001
EurGF
(μmol/L)
         EurGF
(μmol/L)
        
eGFR< 21.3 − 5.1 (− 5.6, − 4.6) < 0.001 eGFR< 8 −21.6 (− 26.4, − 16.8) < 0.001 eGFR< 15.3 −7.6 (− 8.5, − 6.7) < 0.001 eGFR< 20.2 −5.3 (− 5.9, − 4.8) < 0.001 eGFR< 13.9 −8.8 (− 10.6, − 7.0) < 0.001 eGFR< 15.3 − 7.6 (− 8.5, − 6.7) < 0.001
eGFR≥21.3 −0.3 (− 0.3, − 0.2) < 0.001 eGFR≥8 − 0.5 (− 0.6, − 0.3) < 0.001 eGFR≥15.3 −0.3 (− 0.4, − 0.3) < 0.001 eGFR≥20.2 −0.3 (− 0.4, − 0.2) < 0.001 eGFR≥13.9 −0.4 (− 0.6, − 0.3) < 0.001 eGFR≥15.3 −0.4 (− 0.5, − 0.3) < 0.001